DENVER, Colo., Nov 15, 2023 (www.247marketnews.com)- SciSparc Ltd. (NASDAQ: SPRC) reported, this morning, positive topline results from its investigator-initiated Phase IIa trial, indicating that SciSparc’s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer’s patients who participated.
SciSparc is trading at $6.96, up $2.60 (+59.63%), on 2.33M premarket shares.
Its 52-week range is $2.80 to $34.58. It’s pulled well back from this morning’s $8.99 premarket high and has a history of short-term pops, plus it’s a foreign based listing, so swing or scalp is the mindset. If its strong trading volume continues, it may be an interesting morning trade.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
